Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03595592
Title Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Fondazione Michelangelo
Indications

Her2-receptor positive breast cancer

Therapies

Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab

Atezolizumab + Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab

Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: senior | adult
Covered Countries ITA | ESP | DEU | AUT


No variant requirements are available.